HDAC9 and cancer: Particularly, MS-275, a histone deacetylase (HDAC) inhibitor, targets HDAC enzymes and has shown anti-tumor effects in cancers such as leukemia, COAD, uveal melanoma, ESCA, BRCA, and HNSC.